Fresenius Biotech is dedicated to delivering innovative therapeutics to patients with serious illnesses that have a high degree of unmet need. A focal point of our activities is the development of immunotherapeutic products based on innovative antibody technologies. Our focused approach to research and development combined with our international marketing experience enables us to efficiently bring targeted therapeutics to a global patient population.

Our main areas of research:

• Transplantation
• Oncology

Our core competencies:

• Preclinical research and clinical development 
• Worldwide registration of biopharmaceuticals 
• Innovative marketing for specialized indications 
• Attaining market access for innovative products

Founded in 2003, Fresenius Biotech employs approx. 170 employees in Europe and the USA. Fresenius Biotech is a subsidiary of the Fresenius SE healthcare group.